Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
Por:
Orkin, C, Molina, JM, Negredo, E, Arribas, JR, Gathe, J, Eron, JJ, Van Landuyt, E, Lathouwers, E, Hufkens, V, Petrovic, R, Vanveggel, S and Opsomer, M
Publicada:
1 ene 2018
Resumen:
Background Simplified regimens with reduced pill burden and fewer side-effects are desirable for people living with HIV. We investigated the efficacy and safety of switching to a single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide versus continuing a regimen of boosted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate.
Methods EMERALD was a phase-3, randomised, active-controlled, open-label, international, multicentre trial, done at 106 sites across nine countries in North America and Europe. HIV-1-infected adults were eligible to participate if they were treatment-experienced and virologically suppressed (viral load <50 copies per mL for >= 2 months; one viral load of 50-200 copies per mL was allowed within 12 months before screening), and patients with a history of virological failure on non-darunavir regimens were allowed. Randomisation was by computer-generated interactive web-response system and stratified by boosted protease inhibitor use at baseline. Patients were randomly assigned (2: 1) to switch to the open-label study regimen or continue the control regimen. The study regimen consisted of a fixed-dose tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg, which was taken once per day for 48 weeks. The primary outcome was the proportion of participants with virological rebound (confirmed viral load >= 50 copies per mL or premature discontinuations, with last viral load >= 50 copies per mL) cumulative through week 48; we tested non-inferiority (4% margin) of the study regimen versus the control regimen in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT02269917.
Findings The study began on April 1, 2015, and the cutoff date for the week 48 primary analysis was Feb 24, 2017. Of 1141 patients (763 in the study group and 378 in the control group), 664 (58%) had previously received five or more antiretrovirals, including screening antiretrovirals, and 169 (15%) had previous virological failure on a non-darunavir regimen. The study regimen was non-inferior to the control for virological rebound cumulative through week 48 (19 [2. 5%] of 763 patients in the study group vs eight (2 .1%) of 378 patients in the control group; difference 0.4%, 95% CI - 1.5 to 2 . 2; p< 0.0001). No resistance to any study drug was observed. Numbers of discontinuations related to adverse events (11 [1%] of 763 patients in the study group vs four [1%] of 378 patients in the control group) and grade 3-4 adverse events (52 [7%] patients vs 31 [8%] patients) were similar between the two groups. There was a small non-clinically relevant but statistically significant (0 . 2 [SD 1.1] vs 0.1 [1.1], p=0.010) difference between the two groups in change from baseline in total cholesterol to HDL-cholesterol ratio. Only one serious adverse event (pancreatitis in the study group) was deemed as possibly related to the study regimen.
Interpretation Our findings show the safety and efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide as a potential switch option for the treatment of HIV-1 infection in adults with viral suppression.
Filiaciones:
Orkin, C:
Barts Hlth NHS Trust, Royal London Hosp, Dept Infect & Immun, London E1 1BB, England
Molina, JM:
Univ Paris Diderot, St Louis Hosp, AP HP, Dept Infect Dis, Paris, France
:
Germans Trias & Pujol Univ Hosp, Lluita Sida Fdn, Barcelona, Spain
Arribas, JR:
Hosp Univ La Paz, IdiPAZ, Madrid, Spain
Gathe, J:
Therapeut Concepts, Houston, TX USA
Eron, JJ:
Univ N Carolina, Sch Med, Chapel Hill, NC USA
Van Landuyt, E:
Janssen Pharmaceut NV, Beerse, Belgium
Lathouwers, E:
Janssen Pharmaceut NV, Beerse, Belgium
Hufkens, V:
Janssen Pharmaceut NV, Beerse, Belgium
Petrovic, R:
Janssen Pharmaceut NV, Beerse, Belgium
Vanveggel, S:
Janssen Pharmaceut NV, Beerse, Belgium
Opsomer, M:
Janssen Pharmaceut NV, Beerse, Belgium
|